Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis

Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about AbbVie Inc.
AbbVie Inc. News
May 19, 2025 - globenewswire.com
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Cerevel Therapeutics Holdings, Inc. (ABBV) Shareholders
May 19, 2025 - prnewswire.com
Shareholders that lost money on Cerevel Therapeutics Holdings, Inc.(ABBV) should contact The Gross Law Firm about pending Class Action - ABBV
AbbVie Inc. Quantitative Score

About AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
AbbVie Inc. Earnings & Revenue
AbbVie Inc. Financials
Table Compare
Compare ABBV metrics with: | |||
---|---|---|---|
Earnings & Growth | ABBV | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | ABBV | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | ABBV | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | ABBV | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
AbbVie Inc. Income
AbbVie Inc. Balance Sheet
AbbVie Inc. Cash Flow
AbbVie Inc. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
Metrics | Score |
---|---|
Discounted Cash Flows | Strong Buy |
Return on Equity | Strong Sell |
Return on Assets | Strong Sell |
Debt/Equity Ratio | Strong Sell |
Price/Earnings Ratio | Strong Sell |
Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
AbbVie Inc. Dividends
Yield (TTM) | Dividend (TTM) | |
---|---|---|
Infinity% | 6.3800 |
Payment Date | Dividend | Frequency |
---|---|---|
2025-05-15 | 1.64 | Quarterly |
2025-02-14 | 1.64 | Quarterly |
2024-11-15 | 1.55 | Quarterly |
2024-08-15 | 1.55 | Quarterly |
2024-05-15 | 1.55 | Quarterly |
AbbVie Inc. Valuation
Project future cash flows and get the intrinsic value per share.
Historical Market Cap
Shares Outstanding
AbbVie Inc. Executives
Name | Role |
---|---|
Mr. Richard A. Gonzalez | Executive Chairman |
Mr. Robert A. Michael CPA | Chief Executive Officer & Director |
Mr. Jeffrey Ryan Stewart | Executive Vice President & Chief Commercial Officer |
Dr. Azita Saleki-Gerhardt Ph.D. | Executive Vice President & Chief Operating Officer |
Mr. Timothy J. Richmond | Executive Vice President & Chief Human Resources Officer |
Name | Role | Gender | Date of Birth | Pay |
---|---|---|---|---|
Mr. Richard A. Gonzalez | Executive Chairman | Male | 1954 | 8.06M |
Mr. Robert A. Michael CPA | Chief Executive Officer & Director | Male | 1970 | 6.68M |
Mr. Jeffrey Ryan Stewart | Executive Vice President & Chief Commercial Officer | Male | 1969 | 5M |
Dr. Azita Saleki-Gerhardt Ph.D. | Executive Vice President & Chief Operating Officer | 1963 | 4.07M | |
Mr. Timothy J. Richmond | Executive Vice President & Chief Human Resources Officer | Male | 1966 | 3.84M |
AbbVie Inc. Insider Trades
Date | 9 May |
Name | FALK THOMAS J |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 1203 |
Date | 9 May |
Name | TILTON GLENN F |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 1203 |
Date | 9 May |
Name | FREYMAN THOMAS C |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 1203 |
Date | 9 May |
Name | WADDELL FREDERICK H |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 1203 |
Date | 9 May |
Name | Roberts Rebecca B |
Role | Director |
Transaction | Acquired |
Type | A-Award |
Shares | 1203 |
Date | Name | Role | Transaction | Type | Shares |
---|---|---|---|---|---|
9 May | FALK THOMAS J | Director | Acquired | A-Award | 1203 |
9 May | TILTON GLENN F | Director | Acquired | A-Award | 1203 |
9 May | FREYMAN THOMAS C | Director | Acquired | A-Award | 1203 |
9 May | WADDELL FREDERICK H | Director | Acquired | A-Award | 1203 |
9 May | Roberts Rebecca B | Director | Acquired | A-Award | 1203 |